CAPA Commends House Judiciary Committee for “First Step” to Address Patent Abuses & High Drug Prices

Urges Representatives to Take Further Measures Toward Ending Big Pharma’s Patent Abuse

WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others released the following statement commending the House Judiciary Committee for voting, on a bipartisan basis, to advance theAffordable Prescriptions for Patients Through Promoting Competition Act of 2019.  This legislation, introduced by Representatives Jerrold Nadler (D-NY), Doug Collins (R-GA), David Cicilline (D-RI) and Jim Sensenbrenner (R-WI), would take a first step towards addressing product-hopping.

Big Pharma routinely uses underhanded tactics like product-hopping to extend their drug monopolies and prevent or delay American patients from accessing more affordable generic drug and treatment alternatives.  This abuse is no more apparent than in the case of Suboxone, a key treatment for opioid addiction, where patients were switched to a newly patented film strip delivery system based on lies that it was safer. These lies led to a $1.4 billion whistleblower case. The Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 is a step forward in combatting Big Pharma’s abuses by lowering the prices of prescription drugs through faster entry of generic drugs into the market.

The following statements are attributable to Matthew Lane, Executive Director of the Coalition Against Patent Abuse:

“CAPA is pleased to see growing bipartisan support for addressing anticompetitive abuses of America’s patent system by Big Pharma.  Across the country, Americans are paying the price for Big Pharma’s greed.  With skyrocketing prescription drug costs and rising premiums, Americans need Congress to stand up on their behalf and pass legislation that makes meaningful reforms that reduce the cost of prescription drugs.”

“While this legislation represents a step in the right direction, there is more work to be done to stop Big Pharma’s abuse of American patients and our patent system.  Congress must come together and introduce additional reforms such as strengthening the Inter Partes Review process available to the U.S. Patent and Trademark Office to ensure that the agency has the tools necessary to invalidate bad patent filings internally without having to resort to an expensive and time-consuming ligitation process.”

“At a time when many other issues are divided along partisan lines, it is encouraging to see that members of both parties can come together and promote solutions to begin helping American patients.  We urge the House of Representatives to act quickly to pass this legislation and to continue working on more systemic and needed reforms in the months ahead.”

For more information, please visit